Entrar Registro gratuito

Last updated: 25 June 2024 at 4:06pm EST

Otis Brawley Net Worth



Otis Brawley biography

Dr. Otis W. Brawley M.D. serves as Director of the Company. He is a board certified Medical Oncologist. Dr. Brawley is the Bloomberg Distinguished Professor of Oncology and Epidemiology at Johns Hopkins University, a position he has held since January, 2019. Dr. Brawley is a current member of the National Cancer Institute’s (NCI) Board of Scientific Counselors. Dr. Brawley served as the Chief Medical and Scientific Officer at the American Cancer Society from 2007 through 2018, and is a former member of the FDA Oncologic Drug Advisory Committee (ODAC). From April 2001 to December 2018 Dr Brawley was a Professor of Medicine and Oncology at the Emory University School of Medicine and Professor of Epidemiology at the Emory University Rollins School of Public Health. He was also previously a senior investigator at the National Institute of Health (NIH) and NCI. In 2013, he was the recipient of a Special Recognition Award from the American Society of Clinical Oncology. Dr. Brawley received his M.D. from the University of Chicago Pritzker School of Medicine and his B.S. in chemistry from the University of Chicago. Dr. Brawley has served on several nonprofit boards and is currently on the board of The Jackson Laboratory, a nonprofit biomedical research institution.



How old is Otis Brawley?

Otis Brawley is 59, he's been the Director of PDS Biotechnology since 2020. There are 9 older and 5 younger executives at PDS Biotechnology. The oldest executive at PDS Biotechnology Corporation is Richard Sykes, 78, who is the Independent Director.

Insiders trading at PDS Biotechnology

Over the last 5 years, insiders at PDS Biotechnology have traded over $0 worth of PDS Biotechnology stock and bought 54,275 units worth $476,657 . The most active insiders traders include Gregory Gene Freitag, James J Loughlin, eKamil Ali Jackson. On average, PDS Biotechnology executives and independent directors trade stock every 67 days with the average trade being worth of $126,706. The most recent stock trade was executed by Frank Bedu Addo on 2 December 2022, trading 219,535 units of PDSB stock currently worth $1,442,345.



What does PDS Biotechnology do?

pds biotechnology is a clinical stage biopharmaceutical company developing the next-generation of simpler, safer and more effective immunotherapies for cancer and infectious diseases. pds biotechnology’s proprietary versamune® platform vector is based on synthetic and biodegradable lipids which possess a very specific structure and positive charge. the lipids form nanoparticles which activate and are taken up very efficiently by the immune system. the therapeutic product consists of versamune® formulated with a harmless form of the protein or disease-causing agent associated with the particular disease (the antigen) which our immune systems can recognize and respond to. this antigen could be a unique protein expressed only in the cancer cells and not in healthy cells, or it could be a specific viral protein(s) from an infectious virus for example. pds is in the process of completing its first phase 1 human clinical trial in 2015 for pds0101, and has initiated design and preparati



What does PDS Biotechnology's logo look like?

PDS Biotechnology Corporation logo

PDS Biotechnology executives and stock owners

PDS Biotechnology executives and other stock owners filed with the SEC include: